Read Gene

Read Gene Gross Margin

The Gross Margin of Read Gene (RDG.WA) as of Nov 18, 2026 is 93.56 %. In the previous year, Gross Margin was 93.27 % — a change of 0.31% (higher).

Gross Margin

93.56 %

YoY

0.31%

Last updated:

Gross Margin of Read Gene is 2025 93.56 % . Gross Margin of Read Gene was 2024 93.27 % . It decreases by 0.31% higher compared to the previous year.

For Read Gene, the gross margin of 93.6% is up versus 89.1% a few years ago.

The Read Gene Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
44.22 PLN
Jan 1, 2019
11.17 PLN
Jan 1, 2020
61.43 PLN
Jan 1, 2021
89.10 PLN
Jan 1, 2022
85.41 PLN
Jan 1, 2023
89.91 PLN
Jan 1, 2024
93.27 PLN
Jan 1, 2025
93.56 PLN
The Read Gene Gross Margin history
YEARGross MarginYoY
93.56 %+0.31%
93.27 %+3.75%
89.91 %+5.26%
85.41 %-4.14%
89.10 %+45.03%
61.43 %+449.99%
11.17 %-74.74%
44.22 %+167.35%
16.54 %-67.54%
50.95 %+595.38%
7.33 %-75.47%
29.87 %+13,341.56%
0.22 %-58.73%
0.54 %-1,553.85%
-0.04 %-126.67%
0.14 %-73.31%
0.52 %-230.10%
-0.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Gross Margin of Read Gene is 93.56 % in 2025.

Gross Margin of Read Gene changed from 93.27 % to 93.56 %, representing a 0.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Read Gene since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Read Gene

All Key Metrics — Read Gene